Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
125.00    1.20 (0.97%)
Bid:
124.60
Ask:
125.00
Spread: 0.40 (0.321%)
Market Cap: £304.27m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

2 Nov 2020 16:35

RNS Number : 9964D
PureTech Health PLC
02 November 2020
 

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dr. John LaMattina

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

A transfer of Ordinary Shares for nil consideration from Dr. LaMattina to the LaMattina Charitable Trust, of which Dr. LaMattina is a trustee.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

305,296

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

Nil

305,296

e)

Date of the transaction

29 October 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHELLFBBFLEFBV
Date   Source Headline
31st Jan 202211:50 amRNSPRTC's Gelesis Launches Plenity Media Campaign
26th Jan 202212:02 pmRNSPRTC’s Akili to Become Public & $162M Funding
14th Jan 20227:00 amRNSPRTC's Gelesis to Debut on NYSE Today Ticker GLS
7th Jan 202212:00 pmRNSPureTech to Present at JPM Healthcare Conference
6th Jan 20227:00 amRNSLYT-100 Shows Improved AE Profile vs Pirfenidone
5th Jan 202212:05 pmRNSGelesis Adds to BOD & Declared Effective by SEC
20th Dec 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
16th Dec 20217:00 amRNSPRTC Provides Recap Ahead of Catalyst-Rich 2022
8th Dec 202112:00 pmRNSPRTC Presents Data at ACNP Conference For LYT-300
7th Dec 202112:00 pmRNSPRTC's Lymphatic Platform Candidate Human Study
1st Dec 202112:10 pmRNSPRTC: Gelesis' Plenity Now Broadly Available in US
1st Dec 20217:00 amRNSTotal Voting Rights
18th Nov 202112:10 pmRNSPRTC's Gelesis Receives $30M Plenity Order from Ro
16th Nov 202112:00 pmRNSPRTC Publishes Previous LYT-100 MAD Study Results
15th Nov 202112:00 pmRNSPRTC Presents at Two Upcoming Investor Conferences
12th Nov 202112:00 pmRNSPRTC Presents Immunooncology Ph 1/2 Trial at SITC
11th Nov 202112:00 pmRNSFDA Grants PRTC's LYT-200 Orphan Drug Designation
10th Nov 20217:00 amRNSPRTC Receives $100M from Founded Entity Shares
9th Nov 202112:34 pmRNSKRTX and Zai Lab to Develop KarXT in Greater China
9th Nov 20217:00 amRNSPRTC Presents at Jefferies Healthcare Conference
1st Nov 202110:20 amRNSNew Research in Journal Nature on Gelesis Tech
1st Nov 20217:00 amRNSTotal Voting Rights
22nd Oct 20216:00 pmRNSHoldings in Company - TR-1 Correction Announcement
20th Oct 20214:35 pmRNSPrice Monitoring Extension
14th Oct 202112:01 pmRNSPRTC's Vedanta Appoints Chief Legal Officer
12th Oct 20217:00 amRNSAdditional Listing
5th Oct 20211:01 pmRNSVedanta Positive Phase 2 Data in C. Diff Infection
5th Oct 20211:00 pmRNSPRTC's Sonde Launches Mental Health Monitor
29th Sep 20211:01 pmRNSAkili/Shionogi Report Positive Ph2 Data in Japan
20th Sep 20214:02 pmRNSNew PureTech Research Published In Nature Journal
14th Sep 202112:00 pmRNSPRTC to Present at Oppenheimer Healthcare Summit
1st Sep 20217:00 amRNSTotal Voting Rights
24th Aug 20217:00 amRNSHalf-year Report
23rd Aug 202112:00 pmRNSPRTC Presents LYT-100 Ph1 PK & Tolerability at ERS
17th Aug 20211:03 pmRNSAkili Deal Furthers Digital Medicine Leadership
13th Aug 202112:00 pmRNSPRTC Appoints Industry Veteran & Physician as CMO
11th Aug 202112:00 pmRNSPRTC Receives $6.5M; Imbrium to Develop LYT-503
3rd Aug 20217:00 amRNSNotice of Results
2nd Aug 20217:00 amRNSTotal Voting Rights
23rd Jul 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
22nd Jul 20211:03 pmRNSPRTC’s Akili Releases New Features for EndeavorRx
22nd Jul 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
21st Jul 202112:03 pmRNSPureTech’s Vedanta Raises $68M Series D Financing
19th Jul 202112:02 pmRNSPRTC’s Gelesis to Become Public Via Capstar SPAC
9th Jul 202112:00 pmRNSPRTC’s Vor Announces Collaboration with Janssen
8th Jul 20212:05 pmRNSPRTC’s Sonde Announces Collaboration With Qualcomm
7th Jul 202112:00 pmRNSPRTC BeiGene LYT-200 Clinical Trial Agreement
1st Jul 20217:00 amRNSTotal Voting Rights
30th Jun 202112:00 pmRNSPRTC’s Vedanta Announces New Data from IBD Study
28th Jun 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.